NCT01854606View on ClinicalTrials.gov

Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 5, 2013

Primary Completion Date

June 1, 2016

Study Completion Date

June 1, 2016

Conditions
CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
Interventions
DRUG

AEB071

a Protein Kinase C Inhibitor

DRUG

Everolimus

mTOR inhibitor

Trial Locations (15)

10002

Novartis Investigative Site, Taipei

10065

Memorial Sloan Kettering Cancer Center Onc. Dept., New York

20133

Novartis Investigative Site, Milan

20141

Novartis Investigative Site, Milan

37203

Sarah Cannon Research Institute Dept of Onc, Nashville

55131

Novartis Investigative Site, Mainz

63110

Washington University School of Medicine Dept of Oncology., St Louis

76038

Novartis Investigative Site, Rouen

81377

Novartis Investigative Site, München

Unknown

Novartis Investigative Site, New Territories

Novartis Investigative Site, Hong Kong

3015 CE

Novartis Investigative Site, Rotterdam

3075 EA

Novartis Investigative Site, Rotterdam

03080

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY